In addition, by combining clinical studies with in vitro experiments, it has been shown that mTORC plays a role in the development of APS vasculopathy, with mTOR inhibitors able to reduce vascular proliferation in APS nephropathy [35,39]. Here, MTOR is linked to autoimmune polyendocrinopathy.